Contineum Therapeutics (CTNM) Non Operating Income (2023 - 2026)

Contineum Therapeutics' Non Operating Income history runs 4 years deep, the most recent figure standing at -$57000.0 for Q1 2026.

• In Q1 2026, Non Operating Income rose 56.15% year-over-year to -$57000.0; the TTM figure through Mar 2026 stood at $10.4 million (up 132.5% YoY), while the FY2025 annual figure was $8.1 million, up 5057.67% from the prior year.
• Non Operating Income was -$57000.0 for Q1 2026 at Contineum Therapeutics, down from $8.2 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $8.2 million in Q4 2025 to a low of -$167000.0 in Q2 2025.
• Historically, Non Operating Income has averaged $1.5 million across 4 years, with a median of $291000.0 in 2023.
• Biggest YoY gain for Non Operating Income was 17536.17% in 2025; the steepest drop was 2066.67% in 2025.
• A 4-year view of Non Operating Income shows it stood at -$47000.0 in 2023, then changed by 0.0% to -$47000.0 in 2024, then soared by 17536.17% to $8.2 million in 2025, then slumped by 100.7% to -$57000.0 in 2026.
• The last three Non Operating Income figures came in at -$57000.0 (Q1 2026), $8.2 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.